Pancreatic Cancer Research

ResearcherUniversity of MiamiNo recent work listed

Jaime Rafael Merchan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3752-4134; OpenAlex author ID A5046981381. Sources: ClinicalTrials.gov.

Their work

Papers
7
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 trial · 2017: 1 paper · 2018: 1 paper

Papers 7

  1. The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo.2017.10.12↗
  2. Percutaneous Image-Guided Irreversible Electroporation for the Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.jvir.2016.10.023↗
  3. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2015.08.010↗
  4. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Co-author DOI 10.1007/s00280-014-2414-z↗
  5. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Co-author DOI 10.1097/coc.0b013e3182436e8c↗
  6. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Co-author DOI 10.1097/coc.0b013e31821862fb↗
  7. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1186/1471-2407-12-199↗

Trials 1

  1. A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) Principal investigator NCT02576665↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jessica MacIntyre · 6 shared papers, 2012–2018 · strength 0.25
  2. Peter J. Hosein · 5 shared papers, 2012–2018 · strength 0.24
  3. Caio Rocha‐Lima · 4 shared papers, 2012–2017 · strength 0.16
  4. Caio M. Rocha Lima · 3 shared papers, 2013–2018 · strength 0.15
  5. Govindarajan Narayanan · 3 shared papers, 2012–2017 · strength 0.12
  6. Gilberto De Lima Lopes Jr. · 3 shared papers, 2012–2014 · strength 0.10
  7. Sofia Palacio · 1 shared paper, 2018 · strength 0.08
  8. Danny Sleeman · 2 shared papers, 2012–2015 · strength 0.07
  9. Lorraine Portelance · 2 shared papers, 2012–2015 · strength 0.06
  10. Jose M. Yrizarry · 1 shared paper, 2017 · strength 0.06
  11. Hester J. Scheffer · 1 shared paper, 2017 · strength 0.06
  12. Riccardo Antonio Lencioni · 1 shared paper, 2017 · strength 0.06
  13. Soley Bayraktar · 1 shared paper, 2014 · strength 0.04
  14. Heloisa Prado Soares · 1 shared paper, 2014 · strength 0.04
  15. Moh'd M. Khushman · 1 shared paper, 2015 · strength 0.04
  16. Ching-Wei David Tzeng · 1 shared paper, 2015 · strength 0.04
  17. Alberto J. Montero · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.